{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:08:50Z","timestamp":1795108130722,"version":"4.10.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008086","name":"Global Down Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R61AR077495"],"award-info":[{"award-number":["R61AR077495"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["R61HD109748"],"award-info":[{"award-number":["R61HD109748"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jneuroim.2024.578442","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:57:23Z","timestamp":1724389043000},"page":"578442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["JAK inhibition in Down Syndrome Regression Disorder"],"prefix":"10.1016","volume":"395","author":[{"given":"Angela L.","family":"Rachubinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"Sannar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Kammeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda A.","family":"Enriquez-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayleigh R.","family":"Worek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin M.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2024.578442_bb0005","first-page":"132","article-title":"Thyroid disorders in subjects with down syndrome: an update","volume":"89","author":"Amr","year":"2018","journal-title":"Acta Biomed."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0010","doi-asserted-by":"crossref","first-page":"24231","DOI":"10.1073\/pnas.1908129116","article-title":"Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity","volume":"116","author":"Araya","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/dmcn.14127","article-title":"Immunotherapy in selected patients with down syndrome disintegrative disorder","volume":"61","author":"Cardinale","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0020","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ajmg.a.37001","article-title":"Estimates of the live births, natural losses, and elective terminations with down syndrome in the United States","volume":"167a","author":"de Graaf","year":"2015","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0025","first-page":"233","article-title":"Regression: atypical loss of attained functioning in children and adolescents with down syndrome","volume":"41","author":"Devenny","year":"2011","journal-title":"Int Rev Res Intellect Disabil"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0030","article-title":"Multidimensional definition of the interferonopathy of down syndrome and its response to JAK inhibition. Science","volume":"9","author":"Galbraith","year":"2023","journal-title":"Advances"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/NDT.S77307","article-title":"Catatonia in down syndrome; a treatable cause of regression","volume":"11","author":"Ghaziuddin","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0040","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/brainsci11081109","article-title":"Acute regression in down syndrome","volume":"11","author":"Handen","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.621637","article-title":"Case report: improvement following immunotherapy in an individual with seronegative down syndrome disintegrative disorder","volume":"12","author":"Hart","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0050","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/MPG.0000000000002742","article-title":"Routine screening for celiac disease in children with down syndrome improves case finding","volume":"71","author":"Liu","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7060057","article-title":"Acute regression in young people with down syndrome","volume":"7","author":"Mircher","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0060","article-title":"Levodopa-responsive early-onset parkinsonism in down syndrome","volume":"3","author":"Palat","year":"2018","journal-title":"Case Rep. Neurological Med."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0065","series-title":"Regression, Depression, and Psychosis in a Young Adult Female with Down Syndrome: A Case Report","author":"Patel","year":"2017"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0070","series-title":"JAK Inhibition for Treatment of Psoriatic Arthritis in Down Syndrome","author":"Pham","year":"2021"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdcr.2019.02.007","article-title":"Janus kinase inhibition in down syndrome: 2 cases of therapeutic benefit for alopecia areata","volume":"5","author":"Rachubinski","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","article-title":"Unexplained regression in down syndrome: 35 cases from an international down syndrome database","volume":"22","author":"Santoro","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","article-title":"Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder","volume":"14","author":"Santoro","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.940175","article-title":"Assessment and diagnosis of down syndrome regression disorder: international expert consensus","volume":"13","author":"Santoro","year":"2022","journal-title":"Frontiers in neurology"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/DBP.0b013e31828b2b42","article-title":"Developmental regression depression and psychosocial stress","volume":"34","author":"Stein","year":"2013","journal-title":"J. Dev. Behav. Pediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2024.578442_bb0105","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/DBP.0000000000000401","article-title":"Developmental regression, depression, and psychosocial stress in an adolescent with down syndrome","volume":"38","author":"Stein","year":"2017","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0110","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16220","article-title":"Trisomy 21 consistently activates the interferon response","volume":"5","author":"Sullivan","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0115","doi-asserted-by":"crossref","first-page":"14818","DOI":"10.1038\/s41598-017-13858-3","article-title":"Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation","volume":"7","author":"Sullivan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D38JX5F2V2","article-title":"Phenotypic and dermatological manifestations in down syndrome","volume":"17","author":"Sureshbabu","year":"2011","journal-title":"Dermatol. Online J."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.braindev.2015.06.006","article-title":"Effects of donepezil and serotonin reuptake inhibitor on acute regression during adolescence in down syndrome","volume":"38","author":"Tamasaki","year":"2016","journal-title":"Brain Dev."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11091197","article-title":"A systematic review of unexplained early regression in adolescents and adults with down syndrome","volume":"11","author":"Walpert","year":"2021","journal-title":"Brain Sci."},{"issue":"1893\u20131908","key":"10.1016\/j.jneuroim.2024.578442_bb0135","article-title":"Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in down syndrome","volume":"29","author":"Waugh","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.jneuroim.2024.578442_bb0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-023-01399-7","article-title":"Triplication of the interferon receptor locus contributes to hallmarks of down syndrome in a mouse model","author":"Waugh","year":"2023","journal-title":"Nat. Genet. 55(6):1034-1047"},{"key":"10.1016\/j.jneuroim.2024.578442_bb0145","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/0883073814554654","article-title":"Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with down syndrome","volume":"30","author":"Worley","year":"2015","journal-title":"J. Child Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:57:17Z","timestamp":1726513037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"alternative-id":["S0165572824001619"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578442","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibition in Down Syndrome Regression Disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578442","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578442"}}